Ryuji Yasumatsu

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study

Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya et al. · International Journal of Clinical Oncology · 2020 · 54 citations · Full text

Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma

Takahiro Wakasaki, Ryuji Yasumatsu, Ryutaro Uchi et al. · Auris Nasus Larynx · 2019 · 41 citations

Nivolumab Treatment, Neoadjuvant Therapy, Medicine +6

Individualized circulating tumor <scp>DNA</scp> monitoring in head and neck squamous cell carcinoma

Ryunosuke Kogo, Tomomi Manako, Takeshi Iwaya et al. · Cancer Medicine · 2022 · 36 citations · Full text

Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study

Ryuji Yasumatsu, Yasushi Shimizu, Nobuhiro Hanai et al. · International Journal of Clinical Oncology · 2021 · 21 citations · Full text